Oaktree Acquisition Corp. III Life Sciences (OACC) Equity Ratio (2024 - 2026)

Oaktree Acquisition Corp. III Life Sciences filings provide 3 years of Equity Ratio readings, the most recent being 0.04 for Q1 2026.

  • Quarterly Equity Ratio fell 6.74% to 0.04 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.04 through Mar 2026, down 6.74% year-over-year, with the annual reading at 0.03 for FY2025, 7.14% down from the prior year.
  • Equity Ratio hit 0.04 in Q1 2026 for Oaktree Acquisition Corp. III Life Sciences, down from 0.03 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.03 in Q4 2024 and bottomed at 0.04 in Q1 2026.
  • Average Equity Ratio over 3 years is 0.03, with a median of 0.03 recorded in 2025.
  • The largest annual shift saw Equity Ratio dropped 7.14% in 2025 before it dropped 6.74% in 2026.
  • Oaktree Acquisition Corp. III Life Sciences' Equity Ratio stood at 0.03 in 2024, then fell by 7.14% to 0.03 in 2025, then fell by 5.85% to 0.04 in 2026.
  • Per Business Quant, the three most recent readings for OACC's Equity Ratio are 0.04 (Q1 2026), 0.03 (Q4 2025), and 0.03 (Q3 2025).